{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T22:49:00Z","timestamp":1649198940873},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"18","license":[{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Updates to the primary literature and clinical practice guidelines on use of antithrombotic combinations for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) and stenting are reviewed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Up to 8% of patients undergoing PCI have AF and thus require both antiplatelet and anticoagulation therapies, which put them at increased risk for bleeding. Current literature suggests that using a single antiplatelet agent in combination with oral anticoagulation with a direct-acting oral anticoagulant (i.e., dual therapy) is effective and associated with less bleeding risk than triple therapy (dual antiplatelet therapy plus an oral anticoagulant) in patients with AF undergoing PCI with stent placement. The most recently studied dual therapy regimens consist of clopidogrel in combination with apixaban, rivaroxaban, or dabigatran. Guidelines recommend use of an oral anticoagulant plus clopidogrel and aspirin for a short period of time. In general, aspirin should be discontinued in most patients at discharge. In patients with a high risk of thrombosis, aspirin can be continued for up to 1 month. Dual therapy should be continued for 12 months, with oral anticoagulant monotherapy continued thereafter.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A review of current literature on antithrombotic therapy in patients with AF undergoing PCI and subsequent coronary artery stenting indicates that the favored regimen is dual therapy consisting of clopidogrel with rivaroxaban, apixaban, dabigatran, or a vitamin K antagonist. Aspirin may be used in the periprocedural period but should be discontinued thereafter to reduce the risk of bleeding. Decisions regarding specific agents and duration of treatment should be based on thrombotic risk, bleeding risk, and patient preference.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxz152","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T05:05:22Z","timestamp":1567487122000},"page":"1395-1402","source":"Crossref","is-referenced-by-count":2,"title":["Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting"],"prefix":"10.1093","volume":"76","author":[{"given":"Jordan L","family":"Lacoste","sequence":"first","affiliation":[{"name":"Department of Pharmacy, WVU Medicine, Morgantown, WV"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cory L","family":"Hansen","sequence":"additional","affiliation":[{"name":"BCPS AQ-Cardiology, Intermountain Healthcare\u2013Utah Valley Hospital, Provo, UT"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"2019091013283923300_CIT0001","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med."},{"key":"2019091013283923300_CIT0002","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med."},{"key":"2019091013283923300_CIT0003","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med."},{"key":"2019091013283923300_CIT0004","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/CIRCINTERVENTIONS.111.965186","article-title":"Consensus document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary","volume":"4","author":"Faxon","year":"2011","journal-title":"Circ Cardiovasc Interv."},{"key":"2019091013283923300_CIT0005","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest."},{"key":"2019091013283923300_CIT0006","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-2007-996108","article-title":"Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis","volume":"23","author":"Schr\u00f6r","year":"1997","journal-title":"Semin Thromb Hemost."},{"key":"2019091013283923300_CIT0007","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation."},{"key":"2019091013283923300_CIT0008","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-150-6-200903170-00006","article-title":"Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding","volume":"150","author":"Steinhubl","year":"2009","journal-title":"Ann Intern Med."},{"key":"2019091013283923300_CIT0009","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the clopidogrel in unstable angina to prevent recurrent events (CURE) study","volume":"108","author":"Peters","year":"2003","journal-title":"Circulation."},{"key":"2019091013283923300_CIT0010","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","journal-title":"BMJ."},{"key":"2019091013283923300_CIT0011","volume-title":"Plavix (clopidogrel) package insert","year":"2018"},{"key":"2019091013283923300_CIT0012","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","year":"2001","journal-title":"N Engl J Med."},{"key":"2019091013283923300_CIT0013","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin Pharmacol Ther."},{"key":"2019091013283923300_CIT0014","volume-title":"Brillinta (ticagrelor) package insert","year":"2016"},{"key":"2019091013283923300_CIT0015","volume-title":"Effient (prasugrel) package insert","year":"2018"},{"key":"2019091013283923300_CIT0016","volume-title":"Coumadin (warfarin) package insert","year":"2018"},{"key":"2019091013283923300_CIT0017","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5853\/jos.2015.17.2.216","article-title":"Paradoxical procoagulant effect of early doses of warfarin: possible role of non-vitamin K oral anticoagulant in patients with atrial fibrillation-related stroke","volume":"17","author":"Kim","year":"2015","journal-title":"J Stroke."},{"key":"2019091013283923300_CIT0018","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/j.1552-4604.1992.tb03827.x","article-title":"Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects","volume":"32","author":"Freedman","year":"1992","journal-title":"J Clin Pharmacol."},{"key":"2019091013283923300_CIT0019","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation","volume":"154","author":"Lip","year":"2018","journal-title":"Chest."},{"key":"2019091013283923300_CIT0020","doi-asserted-by":"crossref","first-page":"e0164076","DOI":"10.1371\/journal.pone.0164076","article-title":"Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry","volume":"11","author":"Haas","year":"2016","journal-title":"PLoS One."},{"key":"2019091013283923300_CIT0021","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med."},{"key":"2019091013283923300_CIT0022","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med."},{"key":"2019091013283923300_CIT0023","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med."},{"key":"2019091013283923300_CIT0024","volume-title":"Pradaxa (dabigatran) package insert","year":"2018"},{"key":"2019091013283923300_CIT0025","volume-title":"Xarelto (rivaroxaban) package insert","year":"2018"},{"key":"2019091013283923300_CIT0026","volume-title":"Eliquis (apixaban) package insert","year":"2018"},{"key":"2019091013283923300_CIT0027","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1681\/ASN.2016090980","article-title":"Apixaban pharmacokinetics at steady state in hemodialysis patients","volume":"28","author":"Mavrakanas","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"2019091013283923300_CIT0028","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/phar.1905","article-title":"Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment","volume":"37","author":"Stanton","year":"2017","journal-title":"Pharmacotherapy."},{"key":"2019091013283923300_CIT0029","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/jth.13323","article-title":"Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH","volume":"14","author":"Martin","year":"2016","journal-title":"J Thromb Haemost."},{"key":"2019091013283923300_CIT0030","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet."},{"key":"2019091013283923300_CIT0031","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Triple therapy in patients on oral anticoagulation after drug eluting stent implantation","volume":"65","author":"Fiedler","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"2019091013283923300_CIT0032","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med."},{"key":"2019091013283923300_CIT0033","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med."},{"key":"2019091013283923300_CIT0034","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention","volume":"138","author":"Angiolillo","year":"2018","journal-title":"Circulation."},{"key":"2019091013283923300_CIT0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation","author":"January","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"2019091013283923300_CIT0036","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ahj.2017.10.009","article-title":"Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial","volume":"196","author":"Vranckx","year":"2018","journal-title":"Am Heart J."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/76\/18\/1395\/29514884\/zxz152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T15:10:05Z","timestamp":1568128205000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/76\/18\/1395\/5558395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":36,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2019,9,3]]},"published-print":{"date-parts":[[2019,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxz152","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9,15]]},"published":{"date-parts":[[2019,9,3]]}}}